Omalizumab for treatment of refractory urticaria in a patient with metastatic uveal melanoma receiving tebentafusp

Tebentafusp is an immune-mobilizing monoclonal T-cell receptor approved for the treatment of metastatic uveal melanoma. While this agent improves outcomes in patients with unresectable or metastatic uveal melanoma, tebentafusp commonly results in dermatologic cutaneous toxicities. Herein, we present a case of a 32-year-old patient diagnosed with juxtapapillary choroidal melanoma of the left eye with metastases to the liver who developed a diffuse urticarial skin reaction to tebentafusp that was successfully treated with omalizumab.